All In Biotech

Drug Trial Radar · NCT06523959

Avoiding Risks of Thrombosis and Bleeding in Surgery (ARTS) Trial

Avoiding Risks of Thrombosis and Bleeding in Surgery (ARTS) Trial: An International Randomised Controlled Trial Evaluating Apixaban Versus No Anticoagulation in Patients Undergoing General Abdominal, Gynecologic and Urologic Surgery

Last checked: Nov 20, 2026Latest source record: May 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 5,436 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

5,436

Planned (sponsor's estimate)

Start

Jun 6, 2024

Primary completion

Sep 30, 2028

Study completion Dec 31, 2028

Sponsor

Lead sponsor
Clinical Urology and Epidemiology Working GroupGovernment (non-federal)
Sponsor type
Government (non-federal)
Collaborators
Helsinki University Central Hospital; University of Helsinki; University College, London; Population Health Research Institute; Tabriz University of Medical Sciences; Tampere University Hospital; Turku University Hospital; Oulu University Hospital; North Karelia Central Hospital; Albany Medical College; PaijatHame Central Hospital
First posted
Jul 29, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Avoiding Risks of Thrombosis and bleeding in Surgery (ARTS) trial is a pragmatic, international, multicenter, randomized controlled open label trial comparing a direct oral anticoagulant (DOAC) - oral factor Xa inhibitor apixaban - to no anticoagulant among 5,436 patients undergoing abdominal or pelvic surgery at sufficiently similar (and not high) risk of venous thromboembolism (VTE) and bleeding that the net impact - benefit or harm - of thromboprophylaxis remains in doubt.

Conditions

  • Venous Thromboembolism
  • Bleeding

Interventions

  • Apixaban 2.5 MGDrug

    To evaluate the benefits and risks of thromboprophylaxis with oral factor Xa inhibitor Apixaban compared to No anticoagulation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence composite outcome of venous thromboembolism (VTE)Time frame: 90 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Helsinki University Hospital

    Helsinki, Finland · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.